advertisement

Oculus

14 Costing studies; pharmacoeconomics (56)

Showing records 1 to 25

Display all abstracts in classification 14 Costing studies; pharmacoeconomics

Search within classification 14 Costing studies; pharmacoeconomics
84831 Comparing glaucoma medications and general demographics in a sample of glaucoma patients treated in private practice with nationwide registry data in Finland
Parkkari M
Acta Ophthalmologica 2019; 0:
84496 Care pathways for glaucoma detection and monitoring in the UK
Harper RA
Eye 2020; 34: 89-102
84205 Using Adherence-Contingent Rebates on Chronic Disease Treatment Costs to Promote Medication Adherence: Results from a Randomized Controlled Trial
Bilger M
Applied health economics and health policy 2019; 17: 841-855
84892 Association of sex with the global burden of glaucoma: an analysis from the global burden of disease study 2017
Ye X
Acta Ophthalmologica 2020; 0:
85226 The Hub-and-Spoke Management of Glaucoma
Nuzzi R
Frontiers in neuroscience 2020; 14: 180
84575 Improving Patient Access and Reducing Costs for Glaucoma with Integrated Hospital and Community Care: A Case Study from Australia
Ford BK
International journal of integrated care 2019; 19: 5
84906 Modeling the Pharmacotherapy Cost and Outcomes of Primary Open-Angle Glaucoma With Dry Eye
Tachkov K
Frontiers in public health 2019; 7: 363
84600 Taking the strain? Impact of glaucoma on patients' informal caregivers
McDonald L
Eye 2020; 34: 197-204
84920 Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017
Yu L
PLoS ONE 2020; 15: e0227595
85198 Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study
Feldman RM
Clinical Ophthalmology 2020; 14: 729-739
84946 Minimally Invasive Glaucoma Surgery: A Budget Impact Analysis and Evaluation of Patients' Experiences, Preferences, and Values

Ontario health technology assessment series 2019; 19: 1-57
84092 Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States
Albini TA
Ocular Immunology and Inflammation 2020; 28: 164-174
85129 Tilted Optic Disc Frequency in Myopia of Different Degree
Dervisevic E
Medicinski arhiv 2019; 73: 391-393
84465 10-year trends in English primary care glaucoma prescribing
Hogg HDJ
Eye 2020; 34: 192-196
84884 North American cost analysis of brand name versus generic drugs for the treatment of glaucoma
Malvankar-Mehta MS
ClinicoEconomics and outcomes research : CEOR 2019; 11: 789-798
84575 Improving Patient Access and Reducing Costs for Glaucoma with Integrated Hospital and Community Care: A Case Study from Australia
Angell B
International journal of integrated care 2019; 19: 5
84892 Association of sex with the global burden of glaucoma: an analysis from the global burden of disease study 2017
She X
Acta Ophthalmologica 2020; 0:
85226 The Hub-and-Spoke Management of Glaucoma
Marolo P
Frontiers in neuroscience 2020; 14: 180
84092 Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States
Rice JB
Ocular Immunology and Inflammation 2020; 28: 164-174
84205 Using Adherence-Contingent Rebates on Chronic Disease Treatment Costs to Promote Medication Adherence: Results from a Randomized Controlled Trial
Wong TT
Applied health economics and health policy 2019; 17: 841-855
84465 10-year trends in English primary care glaucoma prescribing
Connor A
Eye 2020; 34: 192-196
84884 North American cost analysis of brand name versus generic drugs for the treatment of glaucoma
Feng L
ClinicoEconomics and outcomes research : CEOR 2019; 11: 789-798
84906 Modeling the Pharmacotherapy Cost and Outcomes of Primary Open-Angle Glaucoma With Dry Eye
Vassilev A
Frontiers in public health 2019; 7: 363
84600 Taking the strain? Impact of glaucoma on patients' informal caregivers
Turnbull P
Eye 2020; 34: 197-204
84496 Care pathways for glaucoma detection and monitoring in the UK
Gunn PJG
Eye 2020; 34: 89-102

Issue 21-1

Select Issue


advertisement

Oculus